Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Flora Growth's annualized net income for the quarter that ended in Mar. 2024 was $-13.50 Mil. Flora Growth's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $3.84 Mil. Therefore, Flora Growth's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -351.09%.
The historical rank and industry rank for Flora Growth's Return-on-Tangible-Equity or its related term are showing as below:
FLGC'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -811.06 Med: -186.49 Max: -67.83
Current: -811.06
During the past 5 years, Flora Growth's highest Return-on-Tangible-Equity was -67.83%. The lowest was -811.06%. And the median was -186.49%.
FLGC's Return-on-Tangible-Equity is ranked worse than 97.75% of 933
companies
in the Drug Manufacturers industry
Industry Median: 6.31
vs FLGC: -811.06
Flora Growth Return-on-Tangible-Equity Historical Data
The historical data trend for Flora Growth's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Flora Growth's Return-on-Tangible-Equity
For the Drug Manufacturers - Specialty & Generic subindustry, Flora Growth's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Flora Growth's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Flora Growth's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Flora Growth's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2024) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Flora Growth Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Flora Growth's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are; the commercial and wholesale segment (FGH and Cosechemos subsidiaries), the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries), and the pharmaceuticals segment (Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries). Geographically, the company operates in the United States, Germany, Colombia, the United Kingdom, and Canada. it derives a majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FLGC has been successfully added to your 